Edwards Lifesciences (EW)CEO sold ~$1.52M

~$1.52M

Approx. value · 20K sh @ $76.61

84K

Holds after · shares reported

Traded

Feb 12, 2026

Filed

Feb 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 19, 2025CongressDisclosed sale of EW — reported range $1,001 - $15,000
2. Dec 18, 2025FDAFDA device clearance: HemoSphere Alta Advanced Monitoring Platform (ALTAALL1; ALTACR1; ALTASR1)
3. Dec 22, 2025FDAFDA device approval: SAPIEN M3 Transcatheter Mitral Valve Replacement System
4. Jan 6, 2026Insider · 1 personInsiders: 2 sales (~$971K)
5. Jan 9, 2026InsiderOfficer sold ~$87K of EW shares in the open market
6. Feb 10, 2026Company filing · Form 8-K · ResultsReported its results
7. Feb 12, 2026 · this disclosureInsiderCEO sold ~$1.52M of EW shares in the open market

What came next

1. Feb 12, 2026InsiderCEO sold ~$195K of EW shares in the open market
2. Feb 24, 2026FDAFDA device clearance: HemoSphere Nano Monitor (HSNANO1)
3. Feb 25, 2026InsiderOfficer sold ~$2.01M of EW shares in the open market
4. Mar 2, 2026InsiderOfficer sold ~$974K of EW shares in the open market
5. Mar 11, 2026Insider · 2 peopleInsiders: 3 sales (~$1.2M)
6. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
7. Mar 27, 2026FDARecall: Edwards EVOQUE tricuspid delivery system REF:9850TDS Sterile EO
8. Apr 2, 2026Insider · 1 personInsiders: 2 sales (~$1.8M)
9. Apr 6, 2026InsiderOfficer sold ~$83K of EW shares in the open market
10. Apr 9, 2026Insider · 1 personInsiders: 2 sales (~$1.0M)
11. Apr 17, 2026FDAFDA device clearance: Edwards eSheath+ introducer set
12. Apr 23, 2026Company filing · Form 8-K · ResultsReported its results
13. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
14. May 1, 2026Insider · 1 personInsiders: 2 sales (~$85K)
15. May 2, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position.”
16. May 4, 2026InsiderOfficer sold ~$86K of EW shares in the open market
17. May 7, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“of Certain Officers Approval of the Amended and Restated Long-Term Stock Incentive Compensation Program At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware Corporation (the “Company”), the Company’s stockholders approved the amendment and restatement of the Company’s Long-Term Stock Incentive Compensation Program (the “Long-Term Stock Program”).”
18. May 11, 2026InsiderOfficer sold ~$47K of EW shares in the open market
19. May 12, 2026Insider · 1 personInsiders: 2 sales (~$2.8M)
20. May 15, 2026Insider · 1 personInsiders: 2 sales (~$1.5M)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Edwards Lifesciences

For Edwards Lifesciences, OQRO holds 11 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 21 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EW page.

Other recent filings by Bernard J Zovighian, CEO

• SEC Form 4 at Edwards Lifesciences (EW)Jul 27, 2026
• SEC Form 4 at Edwards Lifesciences (EW)Jun 18, 2026
• SEC Form 4 at Edwards Lifesciences (EW)May 12, 2026
• SEC Form 4 at Edwards Lifesciences (EW)May 12, 2026
• SEC Form 4 at Edwards Lifesciences (EW)Feb 13, 2026

The full history of Bernard J Zovighian, CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Edwards Lifesciences

• SEC Form 4Oct 8, 2026
• SEC Form 4Sep 11, 2026
• SEC Form 4Aug 31, 2026
• SEC Form 4Aug 28, 2026
• SEC Form 4Aug 26, 2026
• SEC Form 4Aug 26, 2026

Everything OQRO holds on this company is on its EW page.